Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Faron Pharmaceuticals Oy

FARN.L ✗ NOT COMPLIANT ☆ Track — members

LSE · Healthcare · Biotechnology & Medical Research ·

UK Micro Cap Analyst: BUY

Last Close

$0.54

▼ -3.41%

Market Cap $106.54M · Vol 7.36K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$106.54M

Micro Cap

Div Yield

0.00%

Annual dividend

EPS Growth

+40.03%

YoY

RSI (14)

30.61

Momentum

Beta

1.43

vs Market

52W High

$2.99

82.05% below

52W Low

$0.50

7.03% above

Volume

7.36K

Avg 95.62K

P/B

N/A

Price-to-book

ROE

239.00%

Return on equity

Free Float

83.56%

Public shares

Shariah Compliance8 STANDARDS

✗ Faron Pharmaceuticals Oy (FARN.L) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does FARN.L pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-3.41%

-5.71%

-6.82%

-21.16%

YTD

-76.13%

-79.54%

-81.33%

-88.24%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-32,013,201.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	239.00%
ROA · ROIC	-183.58% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	N/A
P/FCF	N/A
EPS Growth	+40.03%
Outstanding Shares	199.51M

Technical Indicators

50-Day SMA	$0.57
200-Day SMA	$1.16
RSI (14)	30.61
Beta	1.43
52-Week High	$2.99
52-Week Low	$0.50

Volume Today	7.36K
Avg Daily Volume (30D)	95.62K
Relative Volume	0.08x
Volatility (10D)	16.96
Volatility (30D)	21.78
Free Float	83.56%

Analyst Consensus

BUY

Current Price $0.54

Mean Target $3.65

52W Low$0.50 52W High$2.99

Current

Target

$0.50 $2.99

Current Analyst target

+581.82% upside potential · 3 analysts

Identifiers

ExchangeLSE

FIGIBBG008R5TCG6

ISINFI4000153309

CountryFinland

Sub-IndustryBio Therapeutic Drugs

Earnings DateAug 26, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Faron Pharmaceuticals Oy is a Finland-based clinical stage biopharmaceutical company. The company has three drug candidates all based on mastering immune modulation and, as a result, tackling unmet needs in cancer, preventing organ damage and treating blood count abnormalities. The Company's goal is to build future immunotherapy, i.e., to bring new treatments to patients by affecting the immune system. Faron’s drug candidate, Traumakine, is a drug developed by the Company to prevent multi-organ damage and excessive inflammatory responses. Another drug candidate, Haematokine, promotes the expansion of bone marrow stem cells. It is being developed, e.g., for the treatment of chemotherapyinduced neutropenia (CIN). In neutropenia patients have less blood cells called neutrophils than normal due to cancer treatment.